
Feb 23 (Reuters) - Vir Biotechnology Inc VIR.O:
VIR BIOTECHNOLOGY REPORTS POSITIVE UPDATED PHASE 1 RESULTS FOR PSMA-TARGETING, PRO-XTEN® DUAL-MASKED T-CELL ENGAGER VIR-5500 IN PATIENTS WITH METASTATIC PROSTATE CANCER
VIR BIOTECHNOLOGY INC - VIR-5500 SHOWS FAVORABLE SAFETY PROFILE WITH NO DOSE-LIMITING TOXICITIES
VIR BIOTECHNOLOGY INC: ADVANCING DOSE-EXPANSION COHORTS AND PLAN TO INITIATE OUR REGISTRATIONAL TRIAL IN 2027
VIR BIOTECHNOLOGY INC - DOSE-DEPENDENT ANTI-TUMOR ACTIVITY OBSERVED WITH VIR-5500
VIR BIOTECHNOLOGY: 82% PSA50 & 53% PSA90 DECLINES & RECIST-EVALUABLE OBJECTIVE RESPONSES IN ≥3,000 ΜG/KG Q3W DOSING COHORTS WITH VIR-5500